Adaptimmune Therapeutics annual gross margin
2022
2023
2024
Adaptimmune Therapeutics Gross Margin Growth & History (ADAPY)
Adaptimmune Therapeutics's gross margin was 99.96% for fiscal 2024.
View full Adaptimmune Therapeutics company overviewAdaptimmune Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 99.96% | −0.04 pp |
| 2023 | 2023-12-31 | 100.00% | 0.00 pp |
| 2022 | 2022-12-31 | 100.00% | — |
Adaptimmune Therapeutics quarterly gross margin
Q1.25
Q2.25
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2025 | 2025-06-30 | 81.71% | — |
| Q1 2025 | 2025-03-31 | 87.93% | — |
Adaptimmune Therapeutics gross margin trends
Between the periods ended 2022-12-31 and 2024-12-31, Adaptimmune Therapeutics's gross margin decreased from 100.00% to 99.96%, a change of −0.04 percentage points. The latest reported quarter, Q2 2025, shows 81.71%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptimmune Therapeutics source filings ↗